Emerging studies suggest Retatrutide , a dual stimulator targeting both GLP-1 and another hormone, could provide a significant advancement for body treatment. Preliminary human tests have shown substantial reductions in body mass , potentially exceeding existing obesity medications . Despite this, additional assessment is necessary to completely un